Prospects have greatly improved for AstraZeneca PLC and Merck & Co. Inc.’s PARP inhibitor Lynparza (olaparib) winning approval in a fourth cancer type after the drug met its primary endpoint in the Phase III PROfound trial in second-line prostate cancer.
The companies hope to file the product for this additional indication by the end of the year putting it neck...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)